前列腺癌组织中HNK－1（leu－7）抗原的免疫组织化学研究及其临床意义  

Immunohistochemical study of HNK-1(1eu-7)antigen in prostatic cancer and its clinical significance

作　　者：刘修恒[1] 詹炳炎[1] 王玲珑[1] 张孝斌[1] 吴荣杨[1] 友吉唯夫 吉宽达宽 

机构地区：[1]湖北医科大学附属第一医院泌尿外科,日本滋贺医科大学附属医院泌尿外科

出　　处：《中华泌尿外科杂志》1994年第2期119-122,共4页Chinese Journal of Urology

摘　　要：采用抗ＨＮＫ－１单克隆抗体，对５２例前列腺癌组织的石蜡切片进行免疫组化（ＡＢＣ法）研究。观察免疫组化染色后，阳性癌细胞的比率及染色强度，并探讨抗ＨＮＫ－１免疫组化反应与患者５年生存率及非进展率的关系。结果表明：５２例前列腺癌患者中，４９例呈阳性染色，总阳性率为９４％。阳性癌细胞比率及染色强度均与肿瘤分化度有关。高分化癌的阳性癌细胞比率最高，染色最深；低分化癌的阳性癌细胞比率最低，染色最弱。用Ｋａｐｌａｎ－Ｍｅｉｅｒ法对３３例Ｄ＿２期患者５年生存率及非进展率研究表明：阳性癌细胞比率大于２／３组，其生存率及非进展率显著高于阳性癌细胞比率低于２／３组。结果提示：抗ＨＮＫ－１单克隆抗体可检测前列腺癌的存在，而且ＨＮＫ－１抗原的含量与肿瘤的分化有关，分化越好，ＨＮＫ－１含量越高；反之越低。ＨＮＫ－１抗原的检测对判断前列腺癌患者的预后具有重要意义。Anti-HNK-1 monoclonal antibody(MAb)originally found to direct against natural killer cells, was revealde to be reactive with non-cancerous and cancerous prostatic epithelial cells.However, the clinical significane of HNK-1 antigen remains unknown. In this report,the expression of HNK-1 antigen on prostatic cancer was immunohistochemically investigated by avidin biotin peroxidase comples(ABC) method with anti-HNK-1 MAb. The relationships between the immunoreactions and tumor defferentiation and surveval rate were studied. Of the 52 cases with prostatic cancer, 49 cases (94%)were reactive with anti-HNK-1 MAb and the immunoreaction was associtated with the histological defferetiantion of prostatic cancer. Well differentiated cancer has shown the highest percentage of positive cancer has shown the gighest percentage of pasitive cancre cells and the strongest staining, while poorly differentiated cancer had the lowest percentage and the weakest staining. Further study on the five year surviveal rate and the interval without progression by Kaplan-Meier method on 33 stage D2 cases who had received endocrine therapy revealed that a higher surveval rate and a longer ingterval without progression being observed in the group with more tha twothirds of positive cancer cells. This suggests that expressino of HNK-1 antigen on prostatic cancer may serve as a useful prognostic foactor for patients with prostatic cancer.

关 键 词：前列腺肿瘤 抗原 免疫组织化学 

分 类 号：R737.140.3[医药卫生—肿瘤]